AstraZeneca PLC — Director's Dealing 2018

Oct 24, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PhaseBio Pharmaceuticals Inc (PHAS)
CIK: 0001169245
Period of Report: 2018-10-22

Reporting Person: ASTRAZENECA PLC (10% Owner)
Reporting Person: Zeneca, Inc. (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-10-22	Common Stock	C	2404554	—	Acquired	2404554	Indirect
2018-10-22	Common Stock	P	600000	$5.00	Acquired	3004554	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-10-22	Warrants to Purchase Series C-1 Preferred Stock	$0.12	X	113891	Disposed		Series C-1 Preferred Stock (113891)	Indirect
2018-10-22	Series C-1 Preferred Stock	$	X	113891	Acquired		Common Stock (113891)	Indirect
2018-10-22	Series C-1 Preferred Stock	$	S	2734	Disposed		Common Stock (2734)	Indirect
2018-10-22	Series C-1 Preferred Stock	$	C	1664217	Disposed		Common Stock (1664217)	Indirect
2018-10-22	Series D Preferred Stock	$	C	740337	Disposed		Common Stock (740337)	Indirect

Footnotes

F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F2: Zeneca Inc. is a wholly-owned subsidiary of AstraZeneca PLC. AstraZeneca PLC may be deemed to beneficially own the securities held by Zeneca Inc., but disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, if any.

F3: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering.

F4: The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering.